StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Kwality Pharmaceuticals Limited (KPL)

Pharma · NSE · end-of-day 2026-10-19

₹3,366.00

Day change

-1.08%

1-year

+102.5%

From 52-week high

-12.5%

Weinstein stage

—

Minervini template

—

Kwality Pharmaceuticals Limited closed at ₹3,366.00 on 2026-10-19, up 102% over the past year, 12% below its 52-week high. Over the year its annualised volatility was about 59%, with a largest fall of 14% from a peak.

About Kwality Pharmaceuticals Limited

Kwality Pharmaceuticals Limited manufactures pharmaceutical formulations for domestic and international markets, with products across various therapeutic segments. Its business benefits from growing healthcare expenditure and demand for affordable medicines. Expansion into new therapeutic areas, export markets and manufacturing capacity can support growth. Regulatory compliance, product approvals, raw-material costs, pricing pressure, capacity utilization and competition remain important factors.

Price, RSI and MACD

6M1Y

Price · +102.5% over the period

RSI (14) · 43.8

MACD (12, 26, 9) · histogram -47.04

Price · +102.5% over the period

RSI (14) · 43.8

MACD (12, 26, 9) · histogram -47.04

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Beta
₹3,493 cr	—	—	43.9	78.11	10.53	24.4%	—

Investor methods

Method	Checks	Score	Verdict
Turtle	✗ Close above the prior 55-session high · 3,949.00 ✗ Close above the prior 20-session high · 3,949.00 ✗ Close below the prior 20-session low · 3,226.60 Donchian channel breakout - the Turtle traders' entry.		No signal
Graham	✗ Price at or below the Graham number · Graham number 749.53 ✗ P/E 15 or less · P/E 43.1 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 10.53 — Current ratio 2 or more — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	22/100	Expensive

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
KPL this stock	-3.0	+22.7	+102.5	—	—	—	43.9	10.53	24.4	—	—	—	—	3,493	—	—	78.1	—
BLISSGVS	-8.0	+29.9	+147.2	+312.3	+606.5	+476.9	48.7	5.57	11.5	16.8	—	0.00	29.3	6,650	1,005	142	12.9	1.10
VENUSREM	+0.7	-5.9	+55.8	+252.6	+518.8	+242.4	18.3	3.21	16.8	21.9	—	0.00	13.7	2,130	811	116	86.9	0.88
INDSWFTLAB	-5.7	+50.4	+153.3	+247.2	+287.1	+472.2	51.6	2.21	3.2	3.9	—	0.01	33.4	3,056	665	57	6.8	0.78
MOREPENLAB	+0.5	+108.6	+194.2	+152.6	+242.7	+132.7	47.5	5.34	7.9	10.1	—	0.16	40.2	6,657	1,951	140	2.6	1.46
SHILPAMED	-14.2	+40.1	+113.1	+146.1	+421.3	+189.7	57.3	6.61	9.8	11.4	—	0.25	—	17,130	1,682	297	15.3	0.87
RUBICON	-15.1	-1.7	+60.3	+140.3	—	—	83.8	19.08	22.4	—	—	0.20	61.3	24,587	1,936	288	17.7	0.34
LAURUSLABS	+5.9	+32.7	+83.2	+129.9	+421.9	+235.3	88.9	21.09	18.2	17.9	—	0.45	62.0	1.12L	8,839	1,252	23.3	0.74
ZIMLAB	+2.0	+14.2	+73.3	+101.9	+17.5	—	168.5	2.50	2.1	5.5	—	0.42	21.1	740	397	4	0.8	0.75
ACUTAAS	-5.4	-11.0	+35.0	+97.5	—	—	69.0	16.11	24.0	31.7	—	0.02	49.9	26,636	1,462	387	47.2	0.77
IOLCP	-9.8	+17.8	+108.9	+87.8	+99.0	+56.2	32.0	2.99	7.9	10.7	—	0.07	20.7	5,376	2,524	168	5.7	1.13

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Unichem Laboratories Limited Aartidrugs Solara Active Pharma Sciences Limited Ind-Swift Laboratories Limited Guficbio Smspharma Advanced Enzyme Technologies Limited Rpg Life Sciences Limited

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact